Eli Lilly (LLY)

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

The Vanguard Growth ETF solely focuses on America's largest growth companies.

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Beam Therapeutics' growing pipeline could reward patient investors.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

It is definitely a strong contender.

Maybe you should, too.

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?